interferon alfa-2b renal cell carcinoma

 

 

 

 

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 200826(33):5422-5428. Response, survival, duration of response, and toxicity of treatment were evaluated in patients with advanced renal cell carcinoma receiving a continuous intravenous infusion of 5-fluorouracil (5-FU) and low dose subcutaneous alfa-2b-interferon. Methods. Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors ASCO Annual Meeting Proceedings Part I Abstract 5024. . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007356:227181.doi:10.1056/NEJMoa066838. Purpose: Pembrolizumab, ipilimumab, and pegylated interferon alfa-2b (PEG-IFN) monotherapy are active against melanoma and renal cell carcinoma (RCC). We explored the safety and preliminary antitumor activity of pembrolizumab combined with either ipilimumab or (1987). Interferon treatment of renal cell carcinoma.(1988). Syner- alfa 2b Interferon Vinblastina nel carcinoma del rene in fase gistic antitumor effects of combination immunotherapy with avanzata (abstract). Michael B. Atkins, Joseph A. Sparano, R I Fisher, G R Weiss, Kim Margolin, Karin Fink, L Rubinstein, Louie A, James W. Mier, Rasim Gucalp, Randomized phase II trial ofA simple salting out procedure for extracting DNA from human nucleated cells. Shirley A. Miller, Dale D. Dykes, Herbert F.

Polesky. Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease. There have been case reports of interferon-induced lichen planus in seronegative HCV patients with lymphoproliferative disorders and melanoma. We report the case of a 71-year-old man undergoing treatment with interferon for metastatic renal cell carcinoma (RCC) Rationale: Interferon has long been used as a therapy for renal cell carcinoma. However, optimal dosing schedules have not been identified and patients have been relegated to receiving the highest possible doses for prolonged periods of time. This study is being done to analyze the safety, tolerability, and efficacy of treatment for advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of pembrolizumab pegylated interferon alfa-2b (PegIFN-2b) and pembrolizumab ipilimumab (IPI). Carcinoma, Renal Cell.

Interferon-alpha. Kidney Neoplasms. Sirolimus. Among 16 patients with renal cell carcinoma treated, four had major (clinical partial response) responses, one of which was demonstrated to be a pathologic clinical response after surgical resection of a residual mass.Interferon-alpha. Interleukin-2. Renal-cell carcinoma characteristically appears as a hypervascular tumor. However, RCC with a predominantly papillary tumor pattern or a82. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. With following keyword. Renal Cell Carcinoma. Long Term. Subcutaneous Administration. Advanced Renal. Interferon Alpha2b. Term Results. The management of metastatic renal cell carcinoma (RCC) constitutes a therapeutic challenge and no standard therapy has yet been established. This phase II study aimed to verify the efficacy and tolerability of subcutaneous low dose recombinant interleukin-2 (IL-2) plus alpha interferon (IFN) A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Axel Bex Henk Mallo Martijn Kerst John Haanen Simon Horenblas Gijsbert C. de Gast. Description. Seminars in Surgical Oncology 4:174-177 (1988) Interferon Therapy for Metastatic Renal Cell Carcinoma DAVID A. SWANSON, MD, AND JORGE R. QUESADA, MD From the Departments BACKGROUND: Both alpha-interferon and floxuridine are active in metastatic renal cell carcinoma (MRCC) the two agents have demonstrated antitumor synergism and different clinical toxicities. Description. Seminars in Surgical Oncology 4191-194 (1988) Alpha and Gamma Interferon in the Treatment of Advanced Renal Cell Carcinoma A.D.

H. GEBOERS, MD, P.H.M. DE MULDER, MD, PhD Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993 11:1368.Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. [i] Intralesional interferon alpha 2B cures basal cell carcinoma Interferon alpha 2B is a curative treatment for superficial basal cell carcinomaPhase II Study of Interferon-gamma Versus Interleukin-2 and Interferon- alpha 2b in Metastatic Renal Cell Carcinoma. We treated 11 patients with metastatic renal cell carcinoma with a novel regimen consisting of in vivo primed tumor-infiltrating lymphocytes, interferon-alpha and interleukin-2. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Safety and Tolerability of Pembrolizumab (MK-3475) Pegylated Interferon Alfa-2b and Pembrolizumab Ipilimumab in Participants With Renal Cell Carcinoma.Renal Cell Carcinoma. The most common kind of kidney cancer. Both alpha-interferon and floxuridine are active in metastatic renal cell carcinoma (MRCC) the two agents have demonstrated antitumor synergism and different clinical toxicities. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. Interferon Alfa-2b, Recombinant (3000000 unit) Water (1 ml). Liquid Powder, for solution. Intralesional Intramuscular Subcutaneous.Metastatic Renal Cell Carcinoma. 1. 4.4. Renal Cell Carcinoma.View at Google Scholar View at Scopus. M. J. Ratain, H. M. Golomb, J. W. Vardiman et al Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables, Journal of Clinical Oncology, vol. 6, no. 11, pp. 17141721, 1988. A Phase II Dose Escalation Study of Continuous Daily Subcutaneous Administration of Interferon Alpha-2b in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma. Interferon alfa. From Wikipedia, the free encyclopedia. Jump to: navigation, search.Despite its apparent inactivity, it is still used clinically in the treatment of metastatic renal cell carcinoma, with a reported lower toxicity than the recombinant IFN-2. Abstract. Purpose: Pembrolizumab, ipilimumab, and pegylated interferon alfa-2b (PEG-IFN) monotherapy are active against melanoma and renal cell carcinoma (RCC). Purpose: To determine better the activity of high-dose interleukin-2 (IL-2) either alone or in combination with interferon alfa-2b (IFN Schering-Plough, Kenilworth, NJ) in patients with metastaticConclusion: We conclude that both IL-2 and IL-2/IFN therapy have activity in metastatic renal cell carcinoma. These renal cell carcinoma cancer treatment regimens are provided only to supplement the latest treatment strategies.Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. Keywords renal cell carcinoma, immunotherapy, interferon, pegylated, chemotherapy, capecitabine.(2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. NEJM 356(2): 115-124. Renal Cell Carcinoma. Interferon-alpha. Interleukin-2.AB - Purpose: To determine better the activity of high-dose interieukin-2 (IL-2) either alone or in combination with interferon alfa-2b (IFN Schering-Plough, Kenilworth, NJ) in patients with metastatic renal cell carcinoma, the IL-2 Working Keywords: renal cell carcinoma nephron-sparing surgery [18F]-2-flouro-2-deoxyglucose positron emission tomography metastatic renal cell carcinoma, Peg-interferon alfa-2b radiofrequency ablation percutaneous ultrasound ISBN: 978-91-628-7968-6. Safety and Tolerability of Pembrolizumab (MK-3475) Pegylated Interferon Alfa-2b and Pembrolizumab Ipilimumab in Participants With Renal Cell Carcinoma.Renal Cell Carcinoma. The most common kind of kidney cancer. Interferon alfa-2b. ORGAN SITE gastrointestinal. hemorrhage hepatic infection metabolic/laboratory.28. BC Cancer Agency Genitourinary Tumour Group. BCCA Protocol Summary for Alpha- Interferon (a-IFN) for Advanced Renal Cell Carcinoma. Pembrolizumab, ipilimumab, and pegylated interferon alfa-2b (PEG-IFN) monotherapy are active against melanoma and renal cell carcinoma (RCC). We explored the safety and preliminary antitumor activity of pembrolizumab combined with either ipilimumab or Renal cell carcinoma is an immunogenic tumor, and spontaneous regressions have been documented. Many immune modulators have been used successfully, including the followingSunitinib versus interferon alfa in metastatic renal-cell carcinoma. PURPOSE: We undertook this study to determine the activity and tolerability of sorafenib administered with interferon alfa-2b (IFN-alpha-2b) as first- or second-line therapy in metastatic renal cell cancer (RCC). Renal Cell Carcinoma Renal Cell Cancer Clear Cell Kidney Decitabine. Dacogen 5-Aza-Deoxycytidine Interferon Alfa-2b Intron A RCC. Additional relevant MeSH terms What Interferon Alfa Is Used For: Approved for use in hairy cell leukemia, malignant melanoma, AIDS-related Kaposis sarcoma, follicular non-Hodgkins lymphoma, and condyloma acuminata. Other uses: Chronic myelogenous leukemia (CML), renal cell carcinoma, neuroendocrine tumors Purpose: Pembrolizumab, ipilimumab, and pegylated interferon alfa-2b (PEG-IFN) monotherapy are active against melanoma and renal cell carcinoma (RCC). We explored the safety and preliminary antitumor activity of pembrolizumab combined with either ipilimumab or A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. P Lissoni, S Barni, A Ardizzoia, M Andres, E Scardino, P Cardellini, R Della Bitta, G Tancini. Ilson D H, Motzer R J, Kradin R L, Vogelzang N J, Bajorin D F, Scher H I, Nanus D, OMoore P, Marathias R, Bosl G J: A Phase II trialof interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.J Clin Oncol 7, 1124 (1992).Google Scholar. Between 1989 and 1994, 21 patients with advanced renal cell carcinoma underwent treatment with continuous intravenous infusion of 5-FU, 200 mg/m2/day, and subcutaneous injections of recombinant interferon alfa-2b (IFN-alpha), 1 x 10(6) U/day. Takao Kamai, Yoshiaki Yanai, Kyoko Arai, Hideyuki Abe, Tomonori Yamanishi, Masashi Kurimoto, Ken-Ichiro Yoshida. Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis, BMC Cancer, 2007, 159, DOI: 10.1186/1471-2407-7-159. Condition(s) targeted: Renal Cell Carcinoma. Intervention: Decitabine (Drug) Interferon Alfa-2b (Drug). Phase: Phase 2. Status: Terminated.cell carcinoma (RCC) treated with decitabine and interferon alfa-2b. Secondary Objectives

related notes